More about compounding concerns An open letter from Eli Lilly and Company regarding certain practices related to Mounjaro and Zepbound (June 2024) FDA warns about adverse events from compounded semaglutide (May 2023) Novo Nordisk escalates legal actions to safeguard patients from potentially harmful compounded semaglutide drugs (May 2024) The Center for Medicine in the Public Interest's September 2025 handout explains concerns about mass compounding
Key criteria from Cigna's GLP-1 Coverage Policy: [5] BMI (body mass index) 30 (or 27 with hypertension, type 2 diabetes, sleep apnea, cardiovascular disease) 3 months documented lifestyle efforts (diet and exercise in your medical record) No concurrent GLP-1 use can't take Wegovy with Ozempic or other GLP-1 medications Renewal: Must lose 5% of starting weight to continue coverage Cigna Decision Timelines For medical services (not prescriptions), standard reviews take 5-7 business days
Forgetting protein and resistance training
Do not store reconstituted solution
Approved by the MHRA and recommended by NICE (TA875) in specific circumstances, Wegovy works by mimicking the natural hormone GLP-1, which regulates appetite and food intake
While these actions are similar to those of GLP-1 analogs like Wegovy and Zepbound, there is some evidence that, compared to GLP-1 drugs, amylin analogs are better tolerated and help preserve lean muscle mass